DPPG₂-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo

References

• GLOBOCAN estimated cancer incidence, mortality, and prevalence worldwide in 2018; [cited 2020 August 26]. Available from: http://globocan.iarc.fr
   Google Scholar
• Kamat AM, Hahn NM, Efstathiou JA, et al. Bladder cancer. Lancet. 2016;388(10061):2796–2810.
   PubMed Web of Science ®Google Scholar
• Cambier S, Sylvester RJ, Collette L, et al. EORTC nomograms and risk groups for predicting recurrence, progression, and disease-specific and overall survival in Non-Muscle-invasive stage Ta-T1 urothelial bladder cancer patients treated with 1-3 years of maintenance bacillus Calmette-Guérin. Eur Urol. 2016;69(1):60–69.
   PubMed Web of Science ®Google Scholar
• Witjes JA, Bruins HM, Cathomas R, et al. European association of urology guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2020 guidelines. Eur Urol. 2021;79(1):82–104.
   PubMed Web of Science ®Google Scholar
• Hautmann RE, de Petriconi RC, Volkmer BG. Lessons learned from 1,000 neobladders: the 90-day complication rate. J Urol. 2010;184(3):990–994; quiz 1235.
   PubMed Web of Science ®Google Scholar
• Nielsen ME, Mallin K, Weaver MA, et al. Association of hospital volume with conditional 90-day mortality after cystectomy: an analysis of the national cancer data base. BJU Int. 2014;114(1):46–55.
   PubMed Web of Science ®Google Scholar
• Parker WP, Smelser W, Lee EK, et al. Utilization and outcomes of radical cystectomy for high-grade non-muscle-invasive bladder cancer in elderly patients. Clin Genitourin Cancer. 2017;16(1):e79–e97.
   Web of Science ®Google Scholar
• James ND, Hussain SA, Hall E, BC2001 Investigators, et al. Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer. N Engl J Med. 2012;366(16):1477–1488.
   PubMed Web of Science ®Google Scholar
• Senapati S, Mahanta AK, Kumar S, et al. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther. 2018;3:7.
   PubMed Web of Science ®Google Scholar
• Doxorubicin (Farmacotherapeutisch Kompas); [cited 2018 December]. Available from: https://www.farmacotherapeutischkompas.nl/bladeren/preparaatteksten/d/doxorubicine
   Google Scholar
• Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 1986;46(12 Pt 1):6387–6392.
   PubMed Web of Science ®Google Scholar
• Bhowmik S, Bhowmick S, Maiti K, et al. Two multicenter phase I randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Doxil® or Caelyx® in advanced ovarian cancer. Cancer Chemother Pharmacol. 2018;82(3):521–532.
   PubMed Web of Science ®Google Scholar
• O’Brien MER, Wigler N, Inbar M, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–449.
   PubMed Web of Science ®Google Scholar
• Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC soft tissue and bone sarcoma group. Eur J Cancer. 2001;37(7):870–877.
   PubMed Web of Science ®Google Scholar
• Rifkin RM, Gregory SA, Mohrbacher A, et al. Pegylated liposomal doxorubicin, vincristine, and dexamethasone provide significant reduction in toxicity compared with doxorubicin, vincristine, and dexamethasone in patients with newly diagnosed multiple myeloma: a phase III multicenter randomized trial. Cancer. 2006;106(4):848–858.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Pouli A, Zervas K, Greek Myeloma Study Group, et al. Prospective randomized comparison of vincristine, doxorubicin and dexamethasone (VAD) administered as intravenous bolus injection and VAD with liposomal doxorubicin as first-line treatment in multiple myeloma. Ann Oncol. 2003;14(7):1039–1044.
   PubMed Web of Science ®Google Scholar
• Golombek SK, May JN, Theek B, et al. Tumor targeting via EPR: strategies to enhance patient responses. Adv Drug Deliv Rev. 2018;130:17–38.
   PubMed Web of Science ®Google Scholar
• Wilhelm S, Tavares AJ, Dai Q, et al. Analysis of nanoparticle delivery to tumours. Nat Rev Mater. 2016;1(5):16014.
   Web of Science ®Google Scholar
• Kneidl B, Peller M, Winter G, et al. Thermosensitive liposomal drug delivery systems: state of the art review. Int J Nanomedicine. 2014;9:4387–4398.
   PubMed Web of Science ®Google Scholar
• Manzoor AA, Lindner LH, Landon CD, et al. Overcoming limitations in nanoparticle drug delivery: triggered, intravascular release to improve drug penetration into tumors. Cancer Res. 2012;72(21):5566–5575.
   PubMed Web of Science ®Google Scholar
• van der Heijden AG, Verhaegh G, Jansen CF, et al. Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005;173(4):1375–1380.
   PubMed Web of Science ®Google Scholar
• Hurwitz MD. Hyperthermia and immunotherapy: clinical opportunities. Int J Hyperthermia. 2019;36(sup1):4–9.
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, van der Heijden AG, Lammers RJM, et al. Intravesical radiofrequency induced hyperthermia enhances mitomycin C accumulation in tumour tissue. Int J Hyperthermia. 2018;34(7):988–993.
   PubMed Web of Science ®Google Scholar
• Mikhail AS, Negussie AH, Pritchard WF, et al. Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer. Int J Hyperthermia. 2017;33(7):733–740.
   PubMed Web of Science ®Google Scholar
• Tak WY, Lin SM, Wang Y, et al. Phase III HEAT study adding Lyso-Thermosensitive liposomal doxorubicin to radiofrequency ablation in patients with unresectable hepatocellular carcinoma lesions. Clin Cancer Res. 2018;24(1):73–83.
   PubMed Web of Science ®Google Scholar
• Zimmermann K, Hossann M, Hirschberger J, et al. A pilot trial of doxorubicin containing phosphatidylglycerol based thermosensitive liposomes in spontaneous feline soft tissue sarcoma. Int J Hyperthermia. 2017;33(2):178–190.
   PubMed Web of Science ®Google Scholar
• Van Valenberg FJP, Brummelhuis ISG, Lindner LH, et al. DPPG2-Based thermosensitive liposomes with encapsulated doxorubicin combined with hyperthermia lead to higher doxorubicin concentrations in the bladder compared to conventional application in pigs: a rationale for the treatment of muscle-invasive bladder cancer. Int J Nanomedicine. 2021;(16):75–88.
   PubMed Web of Science ®Google Scholar
• Xiao Z, McCallum TJ, Brown KM, et al. Characterization of a novel transplantable orthotopic rat bladder transitional cell tumour model. Br J Cancer. 1999;81(4):638–646.
   PubMed Web of Science ®Google Scholar
• Guideline on the principles of regulatory acceptance of 3Rs (replacement, reduction, refinement) testing approaches; [cited 2018 September]. Available from: https://www.ema.europa.eu/en/regulatory-acceptance-3r-replacement-reduction-refinement-testing-approaches
   Google Scholar
• Tan WS, Kelly JD. Intravesical device-assisted therapies for non-muscle-invasive bladder cancer. Nat Rev Urol. 2018;15(11):667–685.
   PubMed Web of Science ®Google Scholar
• Limmer S. Zielgerichtete chemotherapie solider tumoren durch thermosensitive liposomen in kombination mit doxorubicin., Gemcitabin und Mitomycin C. Faculty of Veterinary Medicine: Ludwig-Maximilians-Universität München; 2014.
   Google Scholar
• Kim SH, Cho JY, Lee HJ, et al. Ultrasound of the urinary bladder, revisited. J Med Ultrasound. 2007;15(2):77–90.
   Google Scholar
• Wientjes MG, Badalament RA, Au JL. Penetration of intravesical doxorubicin in human bladders. Cancer Chemother Pharmacol. 1996;37(6):539–546.
   PubMed Web of Science ®Google Scholar
• Arends TJ, Falke J, Lammers RJ, et al. Urinary cytokines in patients treated with intravesical mitomycin-C with and without hyperthermia. World J Urol. 2015;33(10):1411–1417.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Apetoh L, Ghiringhelli F, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.
   PubMed Web of Science ®Google Scholar
• Hendricksen K, Molkenboer-Kuenen J, Oosterwijk E, et al. Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy. BJU Int. 2008;101(7):889–893.
   PubMed Web of Science ®Google Scholar
• Arentsen HC, Hendricksen K, Oosterwijk E, et al. Experimental rat bladder urothelial cell carcinoma models. World J Urol. 2009;27(3):313–317.
   PubMed Web of Science ®Google Scholar
• Falke J, Parkkinen J, Vaahtera L, et al. Curcumin as treatment for bladder cancer: a preclinical study of Cyclodextrin-Curcumin complex and BCG as intravesical treatment in an orthotopic bladder cancer rat model. Biomed Res Int. 2018;2018:9634902.
   PubMed Web of Science ®Google Scholar
• van Valenberg FJP, Strauss-Ayali D, Agmon-Gerstein Y, et al. Assessment of the efficacy of repeated instillations of mitomycin C mixed with a thermosensitive hydrogel in an orthotopic rat bladder cancer model. Ther Adv Urol. 2018;10(7):213–221.
   PubMed Web of Science ®Google Scholar
• Weiner AB, Desai AS, Meeks JJ. Tumor location may predict adverse pathology and survival following definitive treatment for bladder cancer: a national cohort study. Eur Urol Oncol. 2019;2(3):304–310.
   PubMed Web of Science ®Google Scholar
• Cheng L, Neumann RM, Scherer BG, et al. Tumor size predicts the survival of patients with pathologic stage T2 bladder carcinoma: a critical evaluation of the depth of muscle invasion. Cancer. 1999;85(12):2638–2647.
   PubMed Web of Science ®Google Scholar
• Hossann M, Hirschberger J, Schmidt R, et al. A heat-activated drug-delivery platform based on phosphatidyl-(oligo)-glycerol nanocarrier for effective cancer treatment. Adv NanoBio Res. 2021;1(6):2000089.
   Google Scholar
• Datta NR, Stutz E, Puric E, et al. A pilot study of radiotherapy and local hyperthermia in elderly patients with muscle-invasive bladder cancers unfit for definitive surgery or chemoradiotherapy. Front Oncol. 2019;9:889.
   PubMed Web of Science ®Google Scholar
• Merten R, Ott O, Haderlein M, et al. Long-term experience of chemoradiotherapy combined with deep regional hyperthermia for organ preservation in high-risk bladder cancer (Ta, Tis, T1, T2)). Oncologist. 2019;24(12):e1341–e50.
   PubMed Web of Science ®Google Scholar
• Ucero AC, Gonçalves S, Benito-Martin A, et al. Obstructive renal injury: from fluid mechanics to molecular cell biology. Open Access J Urol. 2010;2:41–55.
   PubMedGoogle Scholar
• Arends TJ, Nativ O, Maffezzini M, et al. Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus Calmette-Guerin for adjuvant treatment of patients with intermediate- and high-risk non-muscle-invasive bladder cancer. Eur Urol. 2016;69(6):1046–1052.
   PubMed Web of Science ®Google Scholar
• Arends TJ, van der Heijden AG, Witjes JA. Combined chemohyperthermia: 10-year single center experience in 160 patients with nonmuscle invasive bladder cancer. J Urol. 2014;192(3):708–713.
   PubMed Web of Science ®Google Scholar
• Ahmed S, Shahid RK, Bhatt H, et al. Chemotherapy-related thrombocytosis: does it increase the risk of thromboembolism? Oncology. 2012;82(6):327–332.
   PubMed Web of Science ®Google Scholar
• Klinger MH, Jelkmann W. Role of blood platelets in infection and inflammation. J Interferon Cytokine Res. 2002;22(9):913–922.
   PubMed Web of Science ®Google Scholar
• Attia MF, Anton N, Wallyn J, et al. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol. 2019;71(8):1185–1198.
   PubMed Web of Science ®Google Scholar
• Szebeni J, Simberg D, Gonzalez-Fernandez A, et al. Roadmap and strategy for overcoming infusion reactions to nanomedicines. Nat Nanotechnol. 2018;13(12):1100–1108.
   PubMed Web of Science ®Google Scholar
• Panteliadou M, Touloupidis S, Giatromanolaki A, et al. Concurrent administration of liposomal doxorubicin improves the survival of patients with invasive bladder cancer undergoing hypofractionated accelerated radiotherapy (HypoARC). Med Oncol. 2011;28(4):1356–1362.
   PubMed Web of Science ®Google Scholar
• Mazurchuk R, Glaves D, Raghavan D. Magnetic resonance imaging of response to chemotherapy in orthotopic xenografts of human bladder cancer. Clin Cancer Res. 1997;3(9):1635–1641.
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data advanced bladder cancer (ABC) Meta-analysis collaboration. Eur Urol. 2005;48(2):202–205. discussion 5–6.
   PubMed Web of Science ®Google Scholar
• Neoadjuvant chemotherapy in invasive bladder cancer: a systematic review and meta-analysis. Lancet. 2003;361(9373):1927–1934.
   PubMed Web of Science ®Google Scholar
• Ghaferi M, Asadollahzadeh MJ, Akbarzadeh A, et al. Enhanced efficacy of PEGylated liposomal cisplatin: in vitro and in vivo evaluation. Int J Mol Sci. 2020;21(2):559.
   PubMed Web of Science ®Google Scholar